LEO Pharma and ICON enter a strategic partnership to propel clinical trial execution within medical dermatology
Leo Pharma Group and ICON plc today announced a strategic partnership to improve dermatology patients' lives through innovative clinical trials.
ICON plc to present at upcoming Investor Conferences
Mr. Brendan Brennan, CFO of ICON plc, will present at the 2023 Citi Healthcare Conference and Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays Global Healthcare Conference.
ICON Reports Fourth Quarter and Full Year 2022 Results
Full year net business wins of $9,450 million; a net book to bill of 1.22.
ICON Issues Financial Guidance for Full Year 2023
ICON plc announced today its financial guidance for the year ending December 31, 2023.
ICON plc to Present at the 41st Annual J.P. Morgan Healthcare Conference
ICON plc announced today that Dr. Steve Cutler, CEO of ICON plc, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 5:15pm PST/ 8.15pm EST.
ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others
ICON finishes the second half of 2022 with an impressive line-up of awards that commend its healthcare intelligence work and status as an employer of choice.
ICON plc to Present at the 2022 Evercore ISI HealthCONx Conference
ICON plc announced today that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2022 Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022.
ICON Reports Third Quarter 2022 Results
Quarter 3 revenue of $1,942.4 million representing an increase of 3.9% on prior year adjusted revenue and 7.4% on a constant currency organic basis.
ICON selected by BARDA to conduct anthrax vaccine clinical trial
ICON plc announces that it has been selected by BARDA, part of the ASPR, in the Department of HHS, to execute an anthrax vaccine clinical trial.